CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 81.9% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Close

Trade Vir Biotechnology VIR

Sell
 Buy

VirBiotechnology live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

News

Webhose 2026 Oct 08, 11:41

Vir Biotechnology (NASDAQ:VIR) Stock Bumped Down to "Strong Sell" by Zacks Research - Markets Daily

Vir Biotechnology Inc
Webhose 2026 Oct 08, 10:06

Vir Biotechnology (NASDAQ:VIR) Cut to "Strong Sell" at Zacks Research

Vir Biotechnology Inc
Webhose 2026 Oct 08, 06:13

How Upcoming SOLSTICE Phase 2 HDV Data Could Shape Vir Biotechnology's (VIR) Investment Narrative

Vir Biotechnology Inc
Webhose 2026 Oct 07, 15:00

VIR Maintains by HC Wainwright & Co. -- Price Target Raised to $

Vir Biotechnology Inc
Webhose 2026 Oct 07, 14:48

Vir Biotechnology (NASDAQ:VIR) Given New $22.00 Price Target at HC Wainwright

Vir Biotechnology Inc
Webhose 2026 Oct 05, 20:05

Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD's The Liver Meeting® 2026 | Morningstar

Vir Biotechnology Inc
Webhose 2026 Oct 03, 15:22

Vir Biotechnology (VIR) Could Be 48% Undervalued Following Its CFO Appointment

Vir Biotechnology Inc
Webhose 2026 Sep 30, 08:14

Vir Biotechnology, Inc. (NASDAQ:VIR) Stock Rated "Moderate Buy" by Sell-Side Brokerages

Vir Biotechnology Inc
Webhose 2026 Sep 26, 07:38

Bank of America Corp DE Acquires 1,142,539 Shares of Vir Biotechnology, Inc. $VIR

Vir Biotechnology Inc
Webhose 2026 Sep 15, 04:45

Reviewing Tango Therapeutics (NASDAQ:TNGX) and Vir Biotechnology (NASDAQ:VIR) - Stock Observer

Vir Biotechnology Inc

VirBiotechnology news

Latest news

Info

Spread

0.07

Spread (%)

0.6289 %

Leverage

1:5

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Friday

13:31 - 19:59

Monday

13:31-19:59

Tuesday

13:31-19:59

Wednesday

13:31-19:59

Thursday

13:31-19:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

1949367808

Shares Outstanding

169215958

Earnings Date (Next)

0000-00-00

Div Yield

Ex-Dividend Date

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-1.74

Learn more about this instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now

Latest Education Articles

Trustpilot